If you are living with type 2 diabetes, it’s time to talk about your increased risk of cardiovascular events.  

Fortunately, the SURPASS-CVOT clinical research study is currently underway in your area.  We are looking for volunteers to join SURPASS-CVOT, a clinical research trial that will test how effective an investigational study drug is when compared to dulaglutide (an approved diabetes medication) on major adverse cardiovascular events in people with type 2 diabetes mellitus (T2DM), and a history of cardiovascular disease (CVD). 

Any trial-related investigational medications, laboratory tests and assessments that are over and above normal medical care will be provided at no cost to you. Reimbursement may also be available for trial-related expenses (such as travel).

If you would like to know more, please contact us. We will be happy to answer any questions that you may have. We can also schedule an appointment so that you can learn about the study in detail and allow us to check whether you and the study are a good match.

Type of participant we are looking for:

  • Diagnosed with type 2 diabetes
  • Be at least 40 years of age
  • Have established cardiovascular disease (e.g. History of heart attack, stroke, vascular stents, bypass, peripheral artery disease)

Clinicaltrials.gov number
NCT04255433

Who to contact:
Karen Atkinson, Ellen Demmerle
Phone number: 206-768-5338 

BRIDge is a research study to facilitate the understanding of diabetes and immune-mediated diseases. The study consists of a confidential registry where we store your contact, research, and health information, and a sample repository where we keep blood samples for current and future use in our research. The samples will be used for many different studies.

An important part of this study is the sharing of information between researchers of different immune-mediated diseases. The samples and information obtained in this study are part of Benaroya Research Institute’s Immune-Mediated Diseases Registry and Repository.

We may contact you to see if you will come in for additional study visits or to update your health and contact information. We will always tell you what we need and let you decide if you are able to help us at that time. We may also contact you to let you know that you may be eligible for other studies.

Type of participant we are looking for:

  • Diagnosed with type 1 diabetes
  • Relatives of people with type 1 diabetes
  • Age 50 or younger
  • Live in Seattle area

Clinicaltrials.gov number
None

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.benaroyaresearch.org/our-research/diabetes-clinical-research/find-study/bridge-study-of-t1d

TrialNet is an international network dedicated to the study, prevention and early treatment of type 1 diabetes. TrialNet screens relatives of people with type 1 diabetes for their risk of developing the disease and can identify the early stages of T1D years before symptoms appear.  The study also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.

With a simple blood test TrialNet looks for diabetes-related autoantibodies. If autoantibodies are confirmed to be present, participants will be invited to join the monitoring part of the study and they may be eligible to participate in a prevention trial.

Family members can order test kits to be mailed to them, free of charge, to collect a screening sample at home. To learn more or sign up, visit https://www.TrialNet.org

Type of participant we are looking for:

  • Individuals 2.5 through 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)
  • Individuals 2.5 through 20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)

Clinicaltrials.gov number
NCT00097292

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.TrialNet.org

RADIANT - Rare and Atypical Diabetes Network

The Rare and Atypical DIAbetes NeTwork (RADIANT) is dedicated to characterizing (discovering and defining) rare and atypical forms of diabetes.

RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health.

RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Type of participant we are looking for:

  • Ages 0-80 with an atypical form of diabetes

Website for more details about the study:
https://www.atypicaldiabetesnetwork.org/

DERMIS

DERMIS is an investigational study looking to answer the questions of why pump wearers’ skin changes after a number of years.

Type of participant we are looking for:

  • Type 1 adults over the age of 30, who are pump wearers either >20 years or <10 years.

Who to contact:
Dori Khakpour
Email address: dorik@uw.edu

GLIDING

GLIDING: A randomized comparison of transitioning from insulin GLargine to Insulin Degludec usING a bridging dose of glargine versus direct conversion, in patients with type 1 diabetes mellitus, is a small pilot study looking at two regimens (or treatment schedules) for people who switch from taking insulin glargine and insulin degludec.

The main purpose of this study is to see if the participants switching with a bridging dose have less low blood sugars and better blood sugar control vs those who switch with no bridging dose. The results of this research may help design other or larger studies to look at better ways of switching insulins.

Type of participant we are looking for:

  • Patient who are type 1 and whose doctor wishes to change their insulin from Glargine to Degludec.

Who to contact:
Thanmai Kaleru
Email address: tkaleru@uw.edu

Researchers at the University of Washington want to learn more about the effects of insulin on diabetic blood. In particular, our study aims to investigate the effects that insulin has on the behaviour of red blood cells in the blood. The information we learn by doing this study may help advance knowledge in the field of diabetes.

What can you expect during this study, if qualified?

  • You will be asked to attend a lab on the University of Washington campus for about 1 hour
  • Several drops of blood will be extracted from your finger with a lancet, before and after your typical self-injection of insulin
  • You will receive $100 for participation

Type of participant we are looking for:

  • Are between the ages of 18 and 70
  • Have been diagnosed with either Type 1 or Type 2 Diabetes
  • Control your diabetes with rapid-acting insulin

Who to contact:
Arazi Pinhas
Phone number: 561-365-7511
Email address: apinhas@cantab.net

DREAMT Study: Early Markers of Disease and Response to Therapy

We are recruiting newly diagnosed individuals for this study to help scientists predict how abatacept helps preserve insulin production.

In earlier studies, abatacept was shown to slow down beta cell destruction and preserve insulin secretion in people after diagnosis of type 1 diabetes. Abatacept seemed to work better in some people than in others. This study seeks to identify markers that predict how effective abatacept will be in individuals with type 1 diabetes.

Abatacept is approved by the U.S. Food & Drug Administration (FDA) for use in several autoimmune diseases, including rheumatoid arthritis and juvenile idiopathic arthritis, in adults and in children as young as age six. 

Type of participant we are looking for:

  • Diagnosed with type 1 diabetes within the last six months,
  • Age 6 – 55 years,
  • In good general health
  • Live in Seattle area

Clinicaltrials.gov number
NCT04118153

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.benaroyaresearch.org/research-bri/type-1-diabetes-research/find-study/dreamt-study

The Tolerance Using Plasmid (TOPPLE) Study

Patients ages 18 – 45 with type 1 diabetes diagnosed in the past four years have an opportunity to participate in a TrialNet study that is testing the safety of a new treatment, NNC0361-0041. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system.

Earlier studies in the lab show this treatment might retrain the immune system to stop attacking insulin-producing beta cells.

While plasmids are small circular pieces of DNA, they do not change your DNA. They are currently being studied in many clinical trials for other conditions.

As with any medical intervention, there are risks and benefits to participating in this study. Before you decide to participate, a member of our research team will explain all potential risks and benefits and answer any questions you may have.

Type of participant we are looking for:

  • Diagnosed with type 1 diabetes within the past 48 months (four years),
  • 18 – 45 years of age

Clinicaltrials.gov number
 NCT04279613

Who to contact:
Nancy Wickstrom
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.benaroyaresearch.org/research-bri/type-1-diabetes-research/find-study/topple-study